» Articles » PMID: 32158973

Establishment of Patient-derived Three-dimensional Organoid Culture in Renal Cell Carcinoma

Overview
Specialty Urology
Date 2020 Mar 12
PMID 32158973
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Renal cell carcinoma is a heterogeneous kidney cancer, and over 403,000 cases were reported worldwide in 2018. Current methods for studying renal cell carcinoma are limited to two-dimensional (2D) culture of primary cell lines and patient-derived xenograft models. Numerous studies have suggested that 2D culture poorly represents the diversity, heterogeneity, and drug-resistance of primary tumors. The time and cost associated with patient-derived xenograft models poses a realistic barrier to their clinical utility. As a biomimetic model, patient-derived three-dimensional (3D) organoid culture can overcome these disadvantages and bridge the gap between cell culture and patient-derived xenograft models. Here, we establish a patient-derived 3D organoid culture system for clear cell renal cell carcinoma and demonstrate the biomimetic characteristics of our model with respect to both primary kidney cancer and conventional 2D culture.

Materials And Methods: Normal renal tissues and tumor tissues were collected from patients with clear cell renal cell carcinoma. The dissociated cells were cultured as conventional 2D culture and 3D organoid culture. The biomimetic characteristic of the two cultures were compared.

Results: Compared with 2D culture, the 3D organoid cultures retained the characteristic lipid-rich, clear cell morphology of clear cell renal cell carcinoma. Carbonic anhydrase 9 and vimentin were validated as biomarkers of renal cell carcinoma. Expression of the two validated biomarkers was more enhanced in 3D organoid culture.

Conclusions: Patient-derived 3D organoid culture retains the characteristics of renal cell carcinoma with respect to morphology and biomarker expression.

Citing Articles

Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy.

Palacios P, Flores I, Cereceda L, Otero F, Muller M, Brebi P Cancers (Basel). 2025; 17(3).

PMID: 39941775 PMC: 11815936. DOI: 10.3390/cancers17030406.


Organoids as Sophisticated Tools for Renal Cancer Research: Extensive Applications and Promising Prospects.

Huang J, Wang X, Ge S, Lu X, Sun C Cell Mol Bioeng. 2025; 17(6):527-548.

PMID: 39926385 PMC: 11799493. DOI: 10.1007/s12195-024-00825-y.


Construction methods and latest applications of kidney cancer organoids.

Li Z, You Y, Feng B, Chen J, Gao H, Li F Oncol Rev. 2024; 18:1434981.

PMID: 39600908 PMC: 11588466. DOI: 10.3389/or.2024.1434981.


The establishment of kidney cancer organoid line in drug testing.

Tse R, Wong C, Ding X, Cheng C, Chow C, Cheong-Kin Chan R Cancer Med. 2024; 13(12):e7432.

PMID: 38923304 PMC: 11200131. DOI: 10.1002/cam4.7432.


The potential of organoids in renal cell carcinoma research.

Chen Q, Sun X, Li Y, Yang X, Yang X, Xu H BMC Urol. 2024; 24(1):120.

PMID: 38858665 PMC: 11165752. DOI: 10.1186/s12894-024-01511-x.


References
1.
Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View

2.
Morizane R, Bonventre J . Kidney Organoids: A Translational Journey. Trends Mol Med. 2017; 23(3):246-263. PMC: 5442988. DOI: 10.1016/j.molmed.2017.01.001. View

3.
Artegiani B, Clevers H . Use and application of 3D-organoid technology. Hum Mol Genet. 2018; 27(R2):R99-R107. DOI: 10.1093/hmg/ddy187. View

4.
Fatehullah A, Tan S, Barker N . Organoids as an in vitro model of human development and disease. Nat Cell Biol. 2016; 18(3):246-54. DOI: 10.1038/ncb3312. View

5.
Grassi L, Alfonsi R, Francescangeli F, Signore M, De Angelis M, Addario A . Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. Cell Death Dis. 2019; 10(3):201. PMC: 6393468. DOI: 10.1038/s41419-019-1453-0. View